Form 4: BIO-TECHNE Director Julie Bushman Acquires Equity
Insider Transaction Report
BIO-TECHNE Director Julie Bushman acquired 1,640 shares of common stock and 3,777 stock options on October 30, 2025, increasing her beneficial ownership.
Summary
- Julie L. Bushman, a Director of BIO-TECHNE Corp (TECH), reported an acquisition of securities.
- On October 30, 2025, 1,640 shares of common stock were acquired at a price of $0.
- Following this transaction, direct beneficial ownership of common stock stands at 8,775 shares.
- An additional 3,777 stock options were acquired on October 30, 2025, with an exercise price of $0.
- These newly acquired stock options are scheduled to vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
Sentiment
Score: 7
Explanation: The acquisition of common stock and stock options by a director, likely as part of a compensation package, generally indicates alignment of interests and confidence in the company's future prospects.
Positives
- Director Julie Bushman increased her beneficial ownership in BIO-TECHNE Corp, which can signal confidence in the company's future prospects.
- The acquisition of common stock and stock options at a $0 price suggests these are likely part of a compensation package, aligning director interests with shareholder value.
Future Outlook
The newly acquired stock options are scheduled to vest on the earlier of October 30, 2026, or the date of Bio-Techne's 2026 annual meeting of shareholders.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, common for publicly traded companies, and does not provide specific industry-wide context or trends.
Related Party Transactions
- The acquisition of 1,640 shares of common stock and 3,777 stock options by Director Julie L. Bushman at a $0 price is a related party transaction, typically representing equity compensation.
Stakeholder Impact
- Shareholders: The increase in director equity ownership aligns the director's financial interests more closely with those of long-term shareholders.
- Employees/Management: This transaction reflects standard compensation practices for board members, potentially reinforcing a culture of equity-based incentives.
Next Steps
- Vesting of the newly acquired 3,777 stock options on the earlier of October 30, 2026, or the 2026 annual meeting of shareholders.
Key Dates
| Date | Description |
|---|---|
| 10/29/2021 | Grant date for 1,444 stock options with an exercise price of $69.72, expiring 07/31/2030. |
| 10/28/2021 | Grant date for 6,028 stock options with an exercise price of $63.92, expiring 10/29/2030. |
| 10/27/2022 | Grant date for 2,532 stock options with an exercise price of $128.81, expiring 10/28/2031. |
| 10/26/2023 | Grant date for 3,460 stock options with an exercise price of $73.94, expiring 10/27/2032. |
| 10/24/2024 | Grant date for 3,937 stock options with an exercise price of $61.51, expiring 10/26/2033. |
| 10/24/2025 | Grant date for 3,511 stock options with an exercise price of $68.37, expiring 10/24/2034. |
| 10/30/2025 | Date of earliest transaction, involving the acquisition of common stock and new stock options. |
| 10/30/2025 | Grant date for 3,777 stock options with an exercise price of $0, expiring 10/30/2035. |
| 11/03/2025 | Signature date of the Form 4 filing. |
| 10/30/2026 | Earliest vesting date for the newly acquired 3,777 stock options. |
Keywords
BIO-TECHNE, TECH, Form 4, insider transaction, director, stock options, common stock, equity acquisition, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.